Vetoquinol (VETO) Q4 2025 TU earnings summary

Executive summary

• Annual sales reached €525.7 million, up 0.2% at constant exchange rates but down 2.5% on a reported basis, reflecting significant currency headwinds and product range simplification impacts.

• Essential Products sales grew 4.1% at constant exchange rates and 2.1% on a reported basis, now representing 64% of total sales, up from 61% the previous year.

• Strong Q4 performance in Essential Products (+8.0% at constant exchange rates) offset earlier gaps due to manufacturing transfers.

Financial highlights

• Negative currency impacts totaled €14.8 million, affecting all regions except Europe.

• Simplification of Complementary product ranges reduced sales by €9.7 million.

• Q4 sales were €141.5 million, up 4.5% at constant exchange rates.

• Companion animal products accounted for €377 million (72% of sales); farm animal products €149 million (28%).

Outlook and guidance

• Improved product mix is expected to maintain solid profitability for FY 2025.

• Next financial results publication scheduled for March 27, 2026.